Literature DB >> 34297842

Mechanisms of antibiotic resistance of Clostridioides difficile.

Ishani Wickramage1, Patrizia Spigaglia2, Xingmin Sun1.   

Abstract

Clostridioides difficile (CD) is one of the top five urgent antibiotic resistance threats in USA. There is a worldwide increase in MDR of CD, with emergence of novel strains which are often more virulent and MDR. Antibiotic resistance in CD is constantly evolving with acquisition of novel resistance mechanisms, which can be transferred between different species of bacteria and among different CD strains present in the clinical setting, community, and environment. Therefore, understanding the antibiotic resistance mechanisms of CD is important to guide optimal antibiotic stewardship policies and to identify novel therapeutic targets to combat CD as well as other bacteria. Epidemiology of CD is driven by the evolution of antibiotic resistance. Prevalence of different CD strains and their characteristic resistomes show distinct global geographical patterns. Understanding epidemiologically driven and strain-specific characteristics of antibiotic resistance is important for effective epidemiological surveillance of antibiotic resistance and to curb the inter-strain and -species spread of the CD resistome. CD has developed resistance to antibiotics with diverse mechanisms such as drug alteration, modification of the antibiotic target site and extrusion of drugs via efflux pumps. In this review, we summarized the most recent advancements in the understanding of mechanisms of antibiotic resistance in CD and analysed the antibiotic resistance factors present in genomes of a few representative well known, epidemic and MDR CD strains found predominantly in different regions of the world.
© The Author(s) 2021. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34297842      PMCID: PMC8598299          DOI: 10.1093/jac/dkab231

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.758


  102 in total

1.  Constitutive expression of the cryptic vanGCd operon promotes vancomycin resistance in Clostridioides difficile clinical isolates.

Authors:  Wan-Jou Shen; Aditi Deshpande; Kirk E Hevener; Bradley T Endres; Kevin W Garey; Kelli L Palmer; Julian G Hurdle
Journal:  J Antimicrob Chemother       Date:  2020-04-01       Impact factor: 5.790

2.  Transferable resistance to clindamycin, erythromycin, and tetracycline in Clostridium difficile.

Authors:  J Wüst; U Hardegger
Journal:  Antimicrob Agents Chemother       Date:  1983-05       Impact factor: 5.191

3.  Comparative susceptibilities to fidaxomicin (OPT-80) of isolates collected at baseline, recurrence, and failure from patients in two phase III trials of fidaxomicin against Clostridium difficile infection.

Authors:  Ellie J C Goldstein; Diane M Citron; Pamela Sears; Farah Babakhani; Susan P Sambol; Dale N Gerding
Journal:  Antimicrob Agents Chemother       Date:  2011-08-15       Impact factor: 5.191

4.  Tetracycline antibiotics: mode of action, applications, molecular biology, and epidemiology of bacterial resistance.

Authors:  I Chopra; M Roberts
Journal:  Microbiol Mol Biol Rev       Date:  2001-06       Impact factor: 11.056

5.  Comparative genomics analysis of Clostridium difficile epidemic strain DH/NAP11/106.

Authors:  Larry K Kociolek; Dale N Gerding; David W Hecht; Egon A Ozer
Journal:  Microbes Infect       Date:  2018-01-31       Impact factor: 2.700

Review 6.  Pseudomembranous colitis.

Authors:  Priya D Farooq; Nathalie H Urrunaga; Derek M Tang; Erik C von Rosenvinge
Journal:  Dis Mon       Date:  2015-03-11       Impact factor: 3.800

7.  Genomic and expression analysis of the vanG-like gene cluster of Clostridium difficile.

Authors:  Johann Peltier; Pascal Courtin; Imane El Meouche; Manuella Catel-Ferreira; Marie-Pierre Chapot-Chartier; Ludovic Lemée; Jean-Louis Pons
Journal:  Microbiology (Reading)       Date:  2013-05-15       Impact factor: 2.777

8.  The changes of PCR ribotype and antimicrobial resistance of Clostridium difficile in a tertiary care hospital over 10 years.

Authors:  Jong-Han Lee; Yangsoon Lee; Kyungwon Lee; Thomas V Riley; Heejung Kim
Journal:  J Med Microbiol       Date:  2014-04-02       Impact factor: 2.472

9.  Point mutations in Helicobacter pylori's fur regulatory gene that alter resistance to metronidazole, a prodrug activated by chemical reduction.

Authors:  Sung Sook Choi; Peter T Chivers; Douglas E Berg
Journal:  PLoS One       Date:  2011-03-25       Impact factor: 3.240

10.  Five-year Pan-European, longitudinal surveillance of Clostridium difficile ribotype prevalence and antimicrobial resistance: the extended ClosER study.

Authors:  Jane Freeman; Jonathan Vernon; Sally Pilling; Kirsti Morris; Scott Nicolson; Sharie Shearman; Emma Clark; Jose Alejandro Palacios-Fabrega; Mark Wilcox
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2019-12-07       Impact factor: 3.267

View more
  4 in total

1.  Phenotypic and Molecular Characterization of Carbapenem-Heteroresistant Bacteroides fragilis Strains.

Authors:  Zain Baaity; Friederike D von Loewenich; Elisabeth Nagy; László Orosz; Katalin Burián; Ferenc Somogyvári; József Sóki
Journal:  Antibiotics (Basel)       Date:  2022-04-27

Review 2.  Mechanisms and impact of antimicrobial resistance in Clostridioides difficile.

Authors:  Chetna Dureja; Abiola O Olaitan; Julian G Hurdle
Journal:  Curr Opin Microbiol       Date:  2022-01-22       Impact factor: 7.584

3.  Antibiotic Resistance Profile of RT 027/176 Versus Other Clostridioides difficile Isolates in Silesia, Southern Poland.

Authors:  Małgorzata Aptekorz; Krzysztof Sacha; Zygmunt Gofron; Monika Kabała; Celine Harmanus; Ed Kuijper; Gayane Martirosian
Journal:  Pathogens       Date:  2022-08-22

Review 4.  Clostridioides difficile and neurological disorders: New perspectives.

Authors:  Manuele Biazzo; Manuela Allegra; Gabriele Deidda
Journal:  Front Neurosci       Date:  2022-09-20       Impact factor: 5.152

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.